The vaxneuvance market research report is one of a series of new reports that provides vaxneuvance market statistics, including the vaxneuvance industry's global market size, regional shares, competitors with a vaxneuvance market share, detailed vaxneuvance market segments, market trends and opportunities, and any further data you may need to thrive in the vaxneuvance industry. This vaxneuvance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to rising chronic conditions, rising antimicrobial resistance, rising respiratory infections in children, increasing cases of immunocompromised populations, and rising healthcare investments. Major trends in the forecast period include development of needle-free vaccine delivery systems, advancements in cold-chain technologies, integration of AI-powered supply chain optimization, integration with digital health records for tracking immunizations, and innovations in adjuvant systems to boost immune response.
The growing prevalence of pneumonia is expected to drive the expansion of the vaxneuvance market. Pneumonia is an infection that leads to inflammation in the air sacs of the lungs, which can fill with fluid or pus, causing symptoms such as coughing, fever, and difficulty breathing. The rise in pneumonia cases is linked to factors such as viral and bacterial infections, weakened immune systems, air pollution, and an aging population that is more vulnerable to respiratory infections. Vaxneuvance helps by providing protection against pneumonia caused by 15 strains of Streptococcus pneumoniae, reducing the risk of severe infections and related complications. For example, in 2024, Johns Hopkins University reported that the average Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries was 56%, up from 54% in 2023. This high prevalence of pneumonia is fueling the growth of the Vaxneuvance market.
Increased investments in research and development (R&D) are expected to further drive the growth of the vaxneuvance market. R&D investments are rising as there is growing demand for innovation to tackle complex global challenges such as healthcare, sustainability, and digital transformation. These investments support the development of Vaxneuvance by advancing its vaccine technology and expanding its ability to meet evolving healthcare needs. For example, in July 2024, the Department of Health and Social Care in the UK reported that pharmaceutical R&D in 2022 totaled $11.4 billion (£9 billion), representing 0.36% of the nation’s GDP and 18% of all business R&D, the highest among product areas. The increase in R&D investments is helping to drive the growth of the Vaxneuvance market.
A significant trend in the vaxneuvance market is the expansion of its indications, which increases the vaccine's target population. Expanding indications help address unmet medical needs and improve the vaccine's effectiveness in preventing pneumococcal diseases across various age groups. For instance, in June 2022, Merck & Co. Inc. announced that the U.S. Food and Drug Administration expanded Vaxneuvance’s approval to include children aged 6 weeks to 17 years for preventing invasive pneumococcal disease caused by 15 serotypes. This approval highlights the vaccine's clinical importance, though it advises against use in individuals with severe allergies to its components.
The key company operating in the vaxneuvance market is Merck & Co. Inc.
North America was the largest region in the vaxneuvance market in 2024. The regions covered in vaxneuvance report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vaxneuvance market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vaxneuvance is a pneumococcal conjugate vaccine designed to protect against invasive diseases caused by specific strains of Streptococcus pneumoniae in both adults and children. The vaccine works by stimulating the immune system to recognize and combat 15 serotypes of the bacteria, providing broad protection.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for vaxneuvance include pneumonia, meningitis, sepsis, bacteremia, and otitis media. Pneumonia is an infection that inflames the air sacs in the lungs, leading to symptoms such as cough, fever, and difficulty breathing. Vaxneuvance helps prevent pneumococcal pneumonia by targeting specific serotypes of Streptococcus pneumoniae bacteria. The vaccine is distributed through pharmacies and hospitals, with end users including adults, children, and the elderly.
The vaxneuvance market consists of sales of pneumococcal 15-valent conjugate vaccines, adjuvants, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to rising chronic conditions, rising antimicrobial resistance, rising respiratory infections in children, increasing cases of immunocompromised populations, and rising healthcare investments. Major trends in the forecast period include development of needle-free vaccine delivery systems, advancements in cold-chain technologies, integration of AI-powered supply chain optimization, integration with digital health records for tracking immunizations, and innovations in adjuvant systems to boost immune response.
The growing prevalence of pneumonia is expected to drive the expansion of the vaxneuvance market. Pneumonia is an infection that leads to inflammation in the air sacs of the lungs, which can fill with fluid or pus, causing symptoms such as coughing, fever, and difficulty breathing. The rise in pneumonia cases is linked to factors such as viral and bacterial infections, weakened immune systems, air pollution, and an aging population that is more vulnerable to respiratory infections. Vaxneuvance helps by providing protection against pneumonia caused by 15 strains of Streptococcus pneumoniae, reducing the risk of severe infections and related complications. For example, in 2024, Johns Hopkins University reported that the average Pneumonia GAPPD (Global Action Plan for Pneumonia and Diarrhea) score across 15 countries was 56%, up from 54% in 2023. This high prevalence of pneumonia is fueling the growth of the Vaxneuvance market.
Increased investments in research and development (R&D) are expected to further drive the growth of the vaxneuvance market. R&D investments are rising as there is growing demand for innovation to tackle complex global challenges such as healthcare, sustainability, and digital transformation. These investments support the development of Vaxneuvance by advancing its vaccine technology and expanding its ability to meet evolving healthcare needs. For example, in July 2024, the Department of Health and Social Care in the UK reported that pharmaceutical R&D in 2022 totaled $11.4 billion (£9 billion), representing 0.36% of the nation’s GDP and 18% of all business R&D, the highest among product areas. The increase in R&D investments is helping to drive the growth of the Vaxneuvance market.
A significant trend in the vaxneuvance market is the expansion of its indications, which increases the vaccine's target population. Expanding indications help address unmet medical needs and improve the vaccine's effectiveness in preventing pneumococcal diseases across various age groups. For instance, in June 2022, Merck & Co. Inc. announced that the U.S. Food and Drug Administration expanded Vaxneuvance’s approval to include children aged 6 weeks to 17 years for preventing invasive pneumococcal disease caused by 15 serotypes. This approval highlights the vaccine's clinical importance, though it advises against use in individuals with severe allergies to its components.
The key company operating in the vaxneuvance market is Merck & Co. Inc.
North America was the largest region in the vaxneuvance market in 2024. The regions covered in vaxneuvance report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vaxneuvance market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vaxneuvance is a pneumococcal conjugate vaccine designed to protect against invasive diseases caused by specific strains of Streptococcus pneumoniae in both adults and children. The vaccine works by stimulating the immune system to recognize and combat 15 serotypes of the bacteria, providing broad protection.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary indications for vaxneuvance include pneumonia, meningitis, sepsis, bacteremia, and otitis media. Pneumonia is an infection that inflames the air sacs in the lungs, leading to symptoms such as cough, fever, and difficulty breathing. Vaxneuvance helps prevent pneumococcal pneumonia by targeting specific serotypes of Streptococcus pneumoniae bacteria. The vaccine is distributed through pharmacies and hospitals, with end users including adults, children, and the elderly.
The vaxneuvance market consists of sales of pneumococcal 15-valent conjugate vaccines, adjuvants, vaccine administration supplies, and cold chain equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Vaxneuvance Market Characteristics4. Vaxneuvance Market Trends And Strategies5. Vaxneuvance Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Vaxneuvance Pricing Analysis & Forecasts30. Global Vaxneuvance Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Vaxneuvance Market32. Recent Developments In The Vaxneuvance Market
3. Vaxneuvance Market Biologic Drug Characteristics
6. Global Vaxneuvance Growth Analysis And Strategic Analysis Framework
8. Vaxneuvance Market Segmentation
9. Global Vaxneuvance Epidemiology Of Clinical Indications
10. Vaxneuvance Market Regional And Country Analysis
11. Asia-Pacific Vaxneuvance Market
12. China Vaxneuvance Market
13. India Vaxneuvance Market
14. Japan Vaxneuvance Market
15. Australia Vaxneuvance Market
16. South Korea Vaxneuvance Market
17. Western Europe Vaxneuvance Market
18. UK Vaxneuvance Market
19. Germany Vaxneuvance Market
20. France Vaxneuvance Market
21. Eastern Europe Vaxneuvance Market
22. North America Vaxneuvance Market
23. USA Vaxneuvance Market
24. Canada Vaxneuvance Market
25. South America Vaxneuvance Market
26. Middle East Vaxneuvance Market
27. Africa Vaxneuvance Market
28. Vaxneuvance Market Competitive Landscape And Company Profiles
29. Global Vaxneuvance Market Pipeline Analysis
33. Vaxneuvance Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Vaxneuvance Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vaxneuvance market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vaxneuvance ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vaxneuvance market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Pneumonia; Meningitis; Sepsis; Bacteremia; Otitis Media2) By Distribution Channel: Pharmacies; Hospitals
3) By End User: Adults; Children; Geriatric Population
Key Companies Profiled: Merck & Co. Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck & Co. Inc.
